


Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (original) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W is nitrogen or CH;

R¹ is selected from hydrogen or fluorine; and

R^Y is a C₁₋₄ aliphatic group, optionally substituted with N(R²)₂ or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:

each R² is independently selected from hydrogen or a C₁₋₃ aliphatic group optionally substituted with OH, N(R³)₂, or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and wherein:

each R³ is independently selected from hydrogen or a C₁₋₃ aliphatic group;

provided that:

when R¹ is hydrogen and W is CH, then R^Y is other than methyl.

2. (original) The compound of claim 1, wherein R^Y is a C₁₋₄ aliphatic group.

Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

3. (original) The compound of claim 2, wherein R^y is selected from methyl, ethyl, cyclopropyl, *tert*-butyl, or isopropyl.

4. (original) The compound according to claim 3, wherein R^y is selected from methyl, cyclopropyl, or *tert*-butyl.

5. (original) The compound according to claim 1, wherein W is nitrogen.

6. (original) The compound according to claim 1, wherein W is CH.

7. (original) The compound according to claim 1, wherein R^1 is hydrogen.

8. (original) The compound according to claim 1, wherein R^1 is fluorine.


9. (original) The compound according to claim 1, wherein R^y is a C_{1-4} aliphatic group substituted with a 6-membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

10. (original) The compound according to claim 9, wherein R^y is a C_{1-4} aliphatic group substituted with a morpholinyl, piperidinyl, or piperazinyl ring


11. (original) The compound according to claim 1, wherein R^y is a C_{1-4} aliphatic group substituted with $N(R^2)_2$.

12. (original) A compound selected from the group consisting of:


Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340




I-1




I-2




I-3




I-4




I-5




I-6




I-7




I-8




I-9



I-10




I-11




I-12


Applicants: Cornelia J. Forster et al.
 Application No.: 10/632,340




I-13




I-14




I-15



I-16



I-17



and I-18.

13. (original) A pharmaceutically acceptable composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

14. (original) The composition according to claim 13, additionally comprising an additional therapeutic agent selected from a treatment for Alzheimer's Disease (AD), a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating stroke, an agent for treating cardiovascular disease, an antidepressant, an anti-psychotic agent, or an agent for treating diabetes.

15. (previously presented) A method of inhibiting GSK3 kinase activity in a biological sample, comprising the step of contacting said biological sample with:

Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

- a) a composition according to claim 13; or
- b) a compound according to claim 1;

in an amount effective for inhibiting GSK3 kinase activity.

16-17. (canceled)

18. (currently amended) ~~The method according to claim 17, wherein said A~~
method of treating a disease, disorder, or condition ~~[[is]]~~ selected from allergy,
asthma, diabetes, Alzheimer's disease, Huntington's disease, Parkinson's disease,
AIDS associated dementia, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease),
multiple sclerosis (MS), an injury due to head trauma, schizophrenia, anxiety, bipolar
disorder, ~~tauopathy, a spinal cord or peripheral nerve injury, myocardial infarction,~~
~~cardiomyocyte hypertrophy, glaucoma, attention deficit disorder (ADD), depression, a~~
~~sleep disorder, reperfusion/ischemia, stroke, an angiogenic disorder, or baldness, in a~~
patient in need thereof, comprising administering the composition according to claim
13 to said patient.

19-22. (canceled)

23. (currently amended) The method according to claim ~~[[17]]~~ 18,
comprising the additional step of administering to said patient an additional
therapeutic agent selected from a ~~treatment for Alzheimer's Disease (AD), a treatment~~
~~for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for~~
~~asthma, an anti-inflammatory agent, an immunomodulatory or immunosuppressive~~
~~agent, a neurotrophic factor, an agent for treating stroke, an agent for treating~~
~~cardiovascular disease, an antidepressant, an anti-psychotic agent, or an agent for~~
treating diabetes, wherein:

said additional therapeutic agent is appropriate for the disease being treated;

and

Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.